Clinical Trial

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Name: Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors — clinical trial record (NCT07151040)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ODIN

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-08-28; most recent amendment 2026-01-27.

Trial Details

NCT Number	NCT07151040
Lead Sponsor	One-carbon Therapeutics AB
Conditions	Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC), Gastrooesophageal Junction Cancer, Gastric Cancer
Enrollment	43 participants
Start Date	2025-08-22
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-28